Hanmi Pharma Inks $1.26B Licensing Deal with Eli Lilly for GLP-2 Drug, Validating Its Platform Technology

Hanmi Pharmaceutical has licensed out its long-acting GLP-2 drug candidate, Sonefpeglutide, to Eli Lilly in a deal worth up to $1.26 billion.

This move signals that Lilly, a leader in the GLP-1 market for obesity and diabetes, is strategically expanding its portfolio into the GLP-2 area, which focuses on gut health and nutrient absorption.

For Hanmi, this deal is a significant validation of its proprietary LAPSCOVERY platform technology by a global pharmaceutical giant, potentially leading to a re-evaluation of the company's value.

Hanmi Pharmaceutical has signed a massive licensing deal with global pharmaceutical giant Eli Lilly, a truly significant milestone.

This agreement is for 'Sonefpeglutide,' a new drug candidate for Short Bowel Syndrome (SBS), a rare disease. The total value of the deal could reach up to $1.26 billion, including an upfront payment of $75 million. Lilly has secured exclusive global rights, excluding Korea. This isn't just about one successful drug; it's a strategic move by a market leader that tells a much bigger story.

So, why did Lilly, a dominant force in the obesity and diabetes market with its GLP-1 drugs, make such a large investment in a GLP-2 drug? The reasons can be traced through a clear causal chain.

First, Lilly's phenomenal success with GLP-1 drugs like Mounjaro and Zepbound has generated enormous cash flow. To sustain this growth, the company is aggressively expanding, investing tens of billions of dollars into new manufacturing facilities. These massive new factories need a robust pipeline of new products to manufacture, which drives the demand for acquiring promising external assets like Hanmi's.

Second, expanding into the GLP-2 space is a brilliant strategic diversification. While GLP-1 agonists regulate blood sugar and appetite, GLP-2 agonists work to improve gut health and nutrient absorption. This creates a complementary portfolio. Given that some GLP-1 drugs have gastrointestinal side effects, having a drug that promotes gut health is a smart hedge and addresses a clear unmet medical need.

This leads to the question of why Hanmi's drug was so attractive. The key lies in its proprietary 'LAPSCOVERY' platform technology. This technology allows the drug to be administered just once a month, a dramatic improvement in convenience and compliance over the existing daily injection treatment for SBS. Furthermore, the progress of a competitor's GLP-2 drug likely created a sense of urgency for Lilly to secure what it saw as a best-in-class asset.

In conclusion, this deal is a strategic win for both companies. For Lilly, it's a calculated expansion to fortify its leadership in metabolic and gastrointestinal diseases. For Hanmi, it's a powerful external validation of its innovative platform, opening the door for a significant re-rating of its corporate value.

Glossary
GLP-1/GLP-2: Glucagon-like peptides. They are hormones that play different roles in the body. GLP-1 is mainly involved in blood sugar control and appetite, while GLP-2 is involved in the growth and function of the gut.
Licensing Out (L/O): The process of granting another company the rights to develop and commercialize a drug candidate in exchange for payments, such as upfront fees, milestones, and royalties.
Milestone Payment: A payment made by the licensee to the licensor when a specific, predetermined goal (e.g., successful completion of a clinical trial, regulatory approval) is achieved.